US EditionPublished • loading... • Updated
Epigenic Therapeutics Announces Completion of $60 Million Series B Financing to Accelerate Clinical Development of Epigenetic Medicines
- Epigenic Therapeutics announced it has completed a $60 million Series B financing round, led by Lapam Capital, with participation from existing investors Qiming Venture Partners and OrbiMed, as well as new investors including IFSC.
- The funding will support the clinical development of EPI-003 for a chronic hepatitis B functional cure and EPI-001 for hypercholesterolemia treatment.
- Epigenic Therapeutics utilizes its proprietary EPIREG™ technology for gene modulation through precise DNA methylation and histone modification.
- The company aims to deliver safe and effective therapies to patients as soon as possible, focusing on the clinical development of its core pipelines.
Insights by Ground AI
65 Articles
65 Articles
InsideNoVA.com+62 Reposted by 62 other sources
Epigenic Therapeutics Announces Completion of $60 Million Series B Financing to Accelerate Clinical Development of Epigenetic Medicines
SHANGHAI, Sept. 7, 2025 /PRNewswire/ -- Epigenic Therapeutics ("Epigenic"), a clinical-stage innovative drug development company, today announced the completion of a $60 million Series B round of financing led by Lapam Capital, with continued participation from existing investors Qiming Venture…
Coverage Details
Total News Sources65
Leaning Left5Leaning Right7Center22Last UpdatedBias Distribution65% Center
Bias Distribution
- 65% of the sources are Center
65% Center
15%
C 65%
R 21%
Factuality
To view factuality data please Upgrade to Premium
